ERBB2 and gastric cancer: In the DESTINY-Gastric01 trial, 187 Asian HER2-positive GC patients who had received at least two previous lines of therapy, including trastuzumab, were randomised 2:1 to receive T-DXd 6.4 mg/kg every 3 weeks or physician’s choice of chemotherapy.